I'm sure that there are plenty of DNDN investors who will respond that while survival wasn't an official endpoint, it was prespecified, and the FDA's briefing document reviewer stated that survival is the one metric that is valued highly enough that even if it isn't an official endpoint in a trial, the FDA always treats it seriously.
News 
Market Data 
Discover 
AI
